Newbury Pharmaceuticals AB (NEWBRY) Stock Statistics & Valuation Metrics

Newbury Pharmaceuticals AB has a market cap or net worth of kr85.11M. The enterprise value is kr36.14M.

Newbury Pharmaceuticals AB has 30,397,888 shares outstanding. The number of shares has decreased by -2.65% in one year.

Newbury Pharmaceuticals AB’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -22.91%.

The current PE Ratio of Newbury Pharmaceuticals AB is ―. Newbury Pharmaceuticals AB’s PEG ratio is 0.16.

In the last 12 months, Newbury Pharmaceuticals AB had revenue of 36.83M and earned -15.40M in profits. Earnings per share was -0.72.

In the last 12 months, operating cash flow was -11.63M and capital expenditures 0.00, giving a free cash flow of -11.63M billion.

Newbury Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―

Newbury Pharmaceuticals AB upcoming earnings date is Oct 28, 2026, Before Open (Not Confirmed).

Newbury Pharmaceuticals AB as a current ratio of 1.49, with Debt / Equity ratio of 0.00%

In the past 12 months, Newbury Pharmaceuticals AB has paid -4.00K in taxes.

Newbury Pharmaceuticals AB EV to EBITDA ratio is -4.56, with an EV/FCF ratio of -2.08.

Newbury Pharmaceuticals AB has kr12.86M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr12.86M billion.

Gross margin is -345.67%, with operating margin of -38.23%, and net profit margin of -41.83%.

The average price target for Newbury Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―